Evolving Treatment Landscape of EoE: Applying the Latest Evidence to Optimize Care



This activity is provided by Integrity Continuing Education, Inc.


This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc & Sanofi.


Eosinophilic esophagitis (EoE) is a chronic Type 2 inflammatory disease that affects approximately 41 in 100,000 Americans and is associated with a significant clinical and psychosocial burden. EoE is characterized by accumulation of eosinophils, basophils, and mast cells in the esophagus, and when poorly controlled leads to remodeling, narrowing, and fibrosis. Early and accurate diagnosis is crucial for guiding treatment and preventing potentially irreversible esophageal damage. Historically, treatment options have been comprised of dietary restriction, esophageal dilation, proton pump inhibitors, and corticosteroids, all of which often result in suboptimal responses. However, recent advances in understanding of the pathogenesis of EoE have driven the development of novel therapies specifically targeted at various immune mediators. One of these agents, the anti-IL-4/IL-13 dupilumab, became the first FDA-approved treatment for EoE earlier this year.

Join our esteemed faculty as they discuss key strategies to improve the outcomes of patients with EoE. Topics will include early diagnosis, recent clinical trial data regarding new and emerging therapies, and evolving evidence-based recommendations for treatment.


Seema Aceves, MD, PhD
Professor, Pediatrics and Medicine
MRD Endowed Chair in Pediatrics
Director, Eosinophilic Gastrointestinal Disorders Clinic
Division of Allergy Immunology
Rady Children’s Hospital San Diego
University of California
San Diego, California

Ikuo Hirano, MD
Professor of Medicine
Division of Gastroenterology
Department of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Release date: April 5, 2023
Expiration date: April 5, 2024
Estimated time to complete activity: 30 minutes

This educational activity has been designed for allergists and gastroenterologists, specialty nurse practitioners, physician assistants, and internal medicine clinicians involved in the diagnosis and management of patients with EoE.


Upon completion of this educational activity, participants should be able to:

  • Apply knowledge of the clinical manifestations of EoE to improve evaluation and diagnosis of patients and prevent further damage to the esophagus
  • Summarize the pathophysiologic mechanisms of EoE and their rationale as treatment targets for EoE
  • Compare clinical profiles, evidence for use, and approval status of medications used in the treatment of patients with EoE
  • Utilize clinical evidence to individualize treatment and engage in shared decision making for patients with EoE

There are no fees for participating and receiving CME credit for this activity. During the period of April 5, 2023 through April 5, 2024, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 60% or better.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Seema S. Aceves, MD, PhD
Advisory Board: AstraZeneca
Consultant: AstraZeneca, Bristol Meyers Squibb, Nexstone Immunology, Sanofi/Regeneron
Disease State Awareness Education Speaker: Sanofi/Regeneron
Grant Funding: Implicit Biosciences
Patent (UCSD)/Royalties: Takeda

Ikuo Hirano, MD
Clinical Trial Support: Allakos, AstraZeneca, Bristol Meyers Squibb, Celgene, Sanofi/Regeneron, Takeda/Shire
Consultant: Allakos, AstraZeneca, Bristol Meyers Squibb/Receptos, Calyx/Parexel, Celldex, Ellodi/Adare, Phathom Pharmaceuticals, Takeda/Shire, Sanofi/Regeneron
Speaker Bureau: Sanofi/Regeneron

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest